# A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

> **NCT05769608** · PHASE2 · COMPLETED · sponsor: **Mineralys Therapeutics Inc.** · enrollment: 285 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Placebo
- **DRUG:** lorundrostat Dose 1
- **DRUG:** lorundrostat Dose 2

## Key facts

- **NCT ID:** NCT05769608
- **Lead sponsor:** Mineralys Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-13
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769608, "A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05769608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*